Cutting-Edge Advances in Assisted Reproductive Technologies (ART) and In Vitro Fertilization (IVF)

Dear Colleagues,

Reproduction has been and probably will forever remain a fundamental cornerstone of human life. The introduction of In Vitro Fertilization (IVF) over four decades ago cannot be seen as a medical revolution alone. Its impact expanded global social trends and challenged conventional perceptions. Over 10 million live births are only the first evidence of its efficacy. Moreover, adaptations of family types, the prevention of monogenic diseases, fertility preservation, and other breakthroughs that changed medical reality demonstrate the crucial and global impact of assisted reproductive technologies (ARTs) on human lives. The common principle that enables these dramatic developments is scientific excellence led by enthusiastic clinicians and researchers. Intracytoplasmic sperm injection (ICSI), testicular biopsies, improved stimulation protocols, enhanced embryo incubation devised and protocols, egg freezing, and many other achievements made ART safer and more efficient than ever.

Novel inventions are accompanied by new dilemmas. Artificial intelligence (AI) seems like the next revolution. We are only beginning to understand its potential advantages in clinical and laboratory settings. However, scientific, medical, and ethical limitations and controls over the use of AI are required to ensure the safety of this powerful tool. Genetic and epigenetic influences on human health represent additional challenges as the cost of sequencing bioinformatics becomes more affordable than ever. While improved diagnosis capabilities provide new opportunities, they also present a physical task that will evolve and progress over time. In addition to these global advances, specific clinical scenarios still necessitate improved medical solutions. Recurrent implantation failure, fertility preservation among prepubertal boys, and other unsolved clinical scenarios require further research and novel ideas. Indeed, past achievements should encourage and inspire us to launch future discoveries.

Dr. Itai Gat
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• assisted reproductive technologies (ART)
• in vitro fertilization (IVF)
• artificial intelligence
• genetics and epigenetics
• fertility preservation
• male factor